Canterbury Health Laboratories (NZ) Adopts Roche NimbleGen, Inc Microarray Cytogenetics Solution for Mental Retardation Research

MADISON, Wis.--(BUSINESS WIRE)--Roche NimbleGen (SWX:RO) (SWX:ROG) (Pink Sheets: RHHBY) today announced that one of New Zealand’s largest medical laboratories has adopted the NimbleGen CGX Cytogenetics Microarray Solution. Canterbury Health Laboratories has implemented the NimbleGen workflow solution for Cytogenetics including arrays, reagents, instruments, and software at their core facility in Christchurch, New Zealand. The laboratory will be initially implementing the NimbleGen CGX-12 arrays for their research on developmental delay and mental retardation. These arrays provide targeted cytogenetic content based on the analysis of over 40,000 research samples and include several multiplex formats that enable accurate, high-resolution analysis of up to 12 samples in parallel.